Nutraceutical cost-cutting helps bottom line
This article was originally published in The Tan Sheet
Executive Summary
Despite a 2.7 percent dip in quarterly revenues, to $39.4 million from $40.5 million, Nutraceutical International Corp. reports net income rose slightly to $3 million versus $2.9 million in the year-ago period. The Park City, Utah, company said third-quarter diluted earnings per share were 27 cents, compared to 26 cents in the fiscal 2008 third quarter. "Selling, general and administrative expense reduction offset our lower gross margins," attributable to higher raw material and manufacturing costs, Chairman and CEO Bill Gay said July 30
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.